These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16027519)

  • 21. Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.
    Faber A; Sauter A; Hoedt S; Hoermann K; Erben P; Hofheinz RD; Sommer U; Stern-Straeter J; Schultz DJ
    Oncol Rep; 2012 Jul; 28(1):172-8. PubMed ID: 22576800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.
    Bertino P; Porta C; Barbone D; Germano S; Busacca S; Pinato S; Tassi G; Favoni R; Gaudino G; Mutti L
    Thorax; 2007 Aug; 62(8):690-5. PubMed ID: 17311837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
    Toga W; Kondo M; Tokoro A
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.
    Kim E; Matsuse M; Saenko V; Suzuki K; Ohtsuru A; Mitsutake N; Yamashita S
    Thyroid; 2012 Jul; 22(7):717-24. PubMed ID: 22650230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
    Tipping AJ; Mahon FX; Zafirides G; Lagarde V; Goldman JM; Melo JV
    Leukemia; 2002 Dec; 16(12):2349-57. PubMed ID: 12454739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
    Kim JH; Song M; Kang GH; Lee ER; Choi HY; Lee C; Kim JH; Kim Y; Koo BN; Cho SG
    Leuk Res; 2012 Sep; 36(9):1157-64. PubMed ID: 22770910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay.
    Kinsella P; Clynes M; Amberger-Murphy V
    J Neurooncol; 2011 Jan; 101(2):189-98. PubMed ID: 20512610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
    Leisewitz AV; Zimmerman EI; Jones SZ; Yang J; Graves LM
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):779-86. PubMed ID: 18600540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
    Dziba JM; Ain KB
    J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
    Johnson FM; Yang P; Newman RA; Donato NJ
    J Exp Ther Oncol; 2004 Dec; 4(4):317-25. PubMed ID: 15844661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
    O'Reilly T; Wartmann M; Maira SM; Hattenberger M; Vaxelaire J; Muller M; Ferretti S; Buchdunger E; Altmann KH; McSheehy PMJ
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):307-317. PubMed ID: 15723258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
    Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
    Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
    Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.
    Weigel MT; Dahmke L; Schem C; Bauerschlag DO; Weber K; Niehoff P; Bauer M; Strauss A; Jonat W; Maass N; Mundhenke C
    BMC Cancer; 2010 Aug; 10():412. PubMed ID: 20691121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
    Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
    Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.